|
|
Volumn 314, Issue 8, 2015, Pages 758-760
|
|
Questions of safety and fairness raised as right-to-try movement gains steam
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
NEW DRUG;
AMYOTROPHIC LATERAL SCLEROSIS;
DRUG APPROVAL;
DRUG MANUFACTURE;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE ACCESS;
HEALTH CARE COST;
HEALTH CARE POLICY;
HUMAN;
LAW;
MEDICAL ETHICS;
PATIENT RIGHT;
PHASE 1 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
REVIEW;
STEM CELL TRANSPLANTATION;
ADVERSE EFFECTS;
BIOETHICS;
COMPASSIONATE USE;
ECONOMICS;
ETHICS;
LEGISLATION AND JURISPRUDENCE;
PATIENT SELECTION;
SUPPLY AND DISTRIBUTION;
UNITED STATES;
AMYOTROPHIC LATERAL SCLEROSIS;
BIOETHICAL ISSUES;
COLORADO;
COMPASSIONATE USE TRIALS;
DRUG APPROVAL;
DRUGS, INVESTIGATIONAL;
HUMANS;
PATIENT RIGHTS;
PATIENT SELECTION;
STEM CELL TRANSPLANTATION;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84940486408
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2015.7691 Document Type: Review |
|
Times cited : (17)
|
|
References (0)
|